Wilson Therapeutics To Present As A "Next Wave" Company During BioEquity 2015 Conference In Vienna On May 19th

STOCKHOLM, May 6, 2015 /PRNewswire/ -- Wilson Therapeutics AB, a development stage biopharmaceutical company, today announced that CEO Jonas Hansson has been invited to present Wilson Therapeutics as a "Next Wave" company during the annual BioEquity Conference, this year to be held in Vienna. The company will present at 14:30-14:40 CEST on May 19th.

About WTX101
WTX101 is the proprietary bis-choline salt of tetrathiomolybdate, which is currently in Phase 2 testing for Wilson Disease. Tetrathiomolybdate has been evaluated for various indications in clinical studies involving over 500 patients, including 120 patients with Wilson Disease. Through its unique mechanism of action, tetrathiomolybdate has been shown to rapidly lower and control copper levels in both Wilson Disease and other patients. Previous data also suggest that tetrathiomolybdate may stabilize neurological function and reduce the risk of neurological deterioration after initiation of treatment in Wilson Disease patients with neurological involvement. WTX101 has been shown to lower and maintain copper levels with once or twice daily oral dosing. WTX101 has received orphan drug designation in both the United States and the European Union.

About Wilson Disease
Wilsons Disease is a rare autosomal recessive disorder caused by mutations in the ATP7B gene resulting in deficient production of the copper-transporter ATPase-2. Deficient or absent production of ATPase-2 leads to impaired incorporation of Cu into ceruloplasmin and impairment of biliary Cu excretion which allows copper to accumulate in the body. The build-up of copper in liver, brain, kidneys and other tissues of Wilson Disease patients produces significant organ damage and dysfunction. Untreated or inadequately treated disease can result in brain damage, liver failure and death. The overall prevalence of Wilson Disease is estimated to be 1-2 in 30,000.

About Wilson Therapeutics
Wilson Therapeutics is a privately-held biopharmaceutical company focused on improving the lives of patients with Wilson Disease through development of new treatment options and support for increased awareness and education about Wilson Disease. The Company's lead product candidate, WTX101, is currently in clinical development as a treatment for Wilson Disease. Investors in Wilson Therapeutics include Abingworth, HealthCap, MVM Life Science Partners and Neomed. Visit www.wilsontherapeutics.com for more information.

Contact:

Jonas Hansson

CEO

+46709441877

OR

Ami Knoefler

Spark BioComm LLC

+ 1 650 739 9952

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wilson-therapeutics-to-present-as-a-next-wave-company-during-bioequity-2015-conference-in-vienna-on-may-19th-300078313.html

SOURCE Wilson Therapeutics

Help employers find you! Check out all the jobs and post your resume.

Back to news